Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-4578 plus nivolumab and oxaliplatin-based chemotherapy in HER2-negative advanced or recurrent gastric cancer
jRCT2031230389Phase 2Active, not recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- Jan 2024
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in gastric cancer (GC) and esophagogastric junction cancer comparing ONO-4578 combination arm with Placebo combination arm (2 arms). Primary endpoint: Progression-free survival. Started Jan 2024; status: active, not recruiting.
02
Drugs
ONO-4578
03
Conditions
gastric cancer (GC)esophagogastric junction cancer
Beyond the preview
Go deeper on jRCT2031230389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230389.